Bioresorbable scaffolds represent a novel option for treatment of below-the-knee lesions that offer advantages over permanent devices. New data show not only efficacy and safety parity with angioplasty balloon angioplasty, but LIFE-BTK also demonstrated that scaffolds lower BTK limb events.
In this 1-hour webinar, LIFE-BTK trial leaders, a representative from the FDA, and a wound care expert shared their perspectives on the trial, its design, and the ramifications of its findings.
Funded by Abbott
Co-Moderators
Ehrin Armstrong, MD; Niten Singh, MD
Speakers & panel
Brian DeRubertis, MD; Elizabeth Genovese, MD; Raghu Kolluri, MD, MS; Misti Malone, PhD; Sahil A. Parikh, MD; Mahmood Razavi, MD;
Ramon Varcoe, MBBS, MS, PhD
Presentations
LIFE-BTK Results
Brian DeRubertis, MD
Evolving Endpoints, Trial Designs, and Results for Future BTK Trials
Sahil A. Parikh, MD
The Landscape of Emerging Bioresorbable Scaffold Technology
Ramon Varcoe, MBBS, MS, PhD
Wound Outcomes in LIFE-BTK
Raghu Kolluri, MD, MS
Potential Impact of the LIFE-BTK Results on Practice
Mahmood Razavi, MD
The Impact of Clinical Outcomes vs Device Patency for Approval
Misti Malone, PhD
